Abstract
Purpose
Promoter hypermethylation is a common phenomenon in neoplasm. The aims of this study were (a) to compare the methylation profiles in different types of ovarian tumors and (b) to determine the possible relationship between the methylation status and different clinicopathologic characteristics.
Methods
We examined the promoter methylation status of 9 tumor suppressor genes (RARβ2, TMS1, RIZ1, P15, P16, PTEN, MINT31, APC and HIC1) in 89 ovarian cancers, 16 borderline ovarian tumors, 19 benign ovarian tumors, 16 normal ovarian tissue and 5 ovarian cancer cell lines. The methylation status was examined with respect to clinicopathologic characteristics of the ovarian cancer patients.
Results
Methylation indices for ovarian cancer, borderline ovarian tumor, benign ovarian tumor, normal ovarian tissue and ovarian cancer cell lines were 28.8, 20.1, 10.5, 11.8 and 42.2%, respectively. It was significantly higher in ovarian cancer, borderline ovarian tumor and ovarian cancer cell lines (X 2 test, P < 0.001, P = 0.01 and P < 0.001, respectively) than benign or normal ovarian tissues. In ovarian cancer, concurrent methylation of at least two genes (CM2) was associated with early stage disease (X 2 test, P = 0.035) and less recurrence (X 2 test, P = 0.020). When the methylation statuses of the nine genes as well as CM2 were included in multivariate Cox Regression analysis, CM2 was the only independent predictor for survival (P = 0.013).
Conclusion
CM2 was an independent predictor for survival in ovarian cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT (2005) Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 11(2 Pt 1):656–663
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196 (review)
Bestor TH, Tycko B (1996) Creation of genomic methylation patterns. Nat Genet 12:363–367
Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG (2003) Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9(8):2912–2919
Chang HW, Chan A, Kwong DL, Wei WI, Sham JS, Yuen AP (2003) Detection of hypermethylated RIZ1 gene in primary tumor, mouth, and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of nasopharyngeal carcinoma patient. Clin Cancer Res 9:1033–1038
Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM (2000) TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 60:6236–6242
Dong SM, Kim HS, Rha SH, Sidransky D (2001) Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7:1982–1986
Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG (2000) Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275(4):2727–2732
Herman JG, Graff HR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826
Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7(4):536–540
Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA (2001) Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61(9):3573–3577
Ivanova T, Petrenko A, Gritsko T, Vinokourova S, Eshilev E, Kobzeva V, Kisseljov F, Kisseljova N (2002) Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer 2:4
Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163–167 (review)
Lee S, Kim WH, Jung HY, Yang MH, Kang GH (2002) Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 161:1015–1022
Lee JH, Park SJ, Abraham SC, Seo JS, Nam JH, Choi C, Juhng SW, Rashid A, Hamilton SR, Wu TT (2004) Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 23(26):4646–4654
Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF, Schorge JO (2005) Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11:5365–5369
Myohanen SK, Baylin SB, Herman JG (1998) Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res 58:591–593
Ng HH, Bird A (1999) DNA methylation and chromatin modification. Curr Opin Genet Dev 9:158–163
Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA, Gazdar AF (2002) Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8:3324–3331
Sato N, Maehara N, Su GH, Goggins M (2003) Effects of 5-aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 95(4):327–330
Schondorf T, Ebert MP, Hoffmann J, Becker M, Moser N, Pur S, Gohring UJ, Weisshaar MP (2004) Hypermethylation of the PTEN gene in ovarian cancer cell lines. Cancer Lett 207:215–220
Strathdee G, MacKean MJ, Illand M, Brown R (1999) A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18:2335–2341
Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, Brown R (2001) Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158:1121–1127
Suh SI, Cho JW, Baek WK, Suh MH, Carson DA (2000) Lack of mutation at p16INK4A gene but expression of aberrant p16INK4A RNA transcripts in human ovarian carcinoma. Cancer Lett 153:175–182
Surani MA (1998) Imprinting and the initiation of gene silencing in the germ line. Cell 93:309–312
Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, Mita H, Imai K, Tokino T, Kudo R (2004) Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 10:2000–2006
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP (1999a) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96(15):8681–8686
Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP (1999b) Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59(21):5438–5442
Zysman MA, Chapman WB, Bapat B (2002) Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 160:795–800. Erratum in: Am J Pathol 160:2311
Acknowledgments
This work was supported by the Committee on Research and Conference Grant Council, The University of Hong Kong, Hong Kong (10205921/11733/20900/301/01).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tam, K.F., Liu, V.W.S., Liu, S.S. et al. Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol 133, 331–341 (2007). https://doi.org/10.1007/s00432-006-0178-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-006-0178-5